Antibiotics Usage in Pediatric Orthopaedic Percutaneous Surgery (APOPS)

This patient population will be recruited from the cohort presenting to Women and Children's Hospital for percutaneous fixation of pediatric supracondylar humerus fractures. Participants will be asked to assent to take part in the study and their parents or guardian will be asked to sign an informed consent. Patients will be randomized to a treatment group that receives one dose of pre-operative antibiotics or one that does not.

Start Date: August 18, 2017

Completion Date: December 1, 2020

Status: Recruiting

Assessment of Lung Movement With Computed Tomography (CT)

Interstitial lung disease (ILD) is a group of lung disorders in which the lung tissues become inflamed and then damaged. Idiopathic Pulmonary Fibrosis (IPF) is one of the subtypes of ILD which has characteristic histological and CT features. It is well known that microscopic fibrosis occurs in the lungs of IPF patients well before the structural changes of fibrosis become apparent on CT.

Start Date: July 1, 2017

Completion Date: July 31, 2018

Status: Recruiting

Dietary Riboflavin (Vitamin B-2) and Cornea Cross-Linking

Corneal ectasia as a complication from refractive (LASIK) surgery as well as keratoconus is a slowly progressive condition that results in high patient morbidity. Treatment options aim to stabilize the shape of the cornea using rigid contact lenses, surgical insertion of stiff plastic intrastromal rings, corneal cross linking, and ultimately corneal transplant in severe patients.

Start Date: May 1, 2017

Completion Date: January 1, 2018

Status: Recruiting

The Liver Health Study for Patients With NAFLD

The study has two phases. In Phase I, liver samples from patients undergoing bariatric surgery or a diagnostic liver biopsy will be tested for the ability to burn fatty acids. In Phase II, patients with nonalcoholic fatty liver disease will participate in either a nine-month lifestyle treatment program or undergo standard care. The goal is to determine how weight loss and exercise improve liver health. Inpatient comprehensive metabolic tests are performed before and after the nine-months.

Start Date: April 26, 2017

Completion Date: May 31, 2029

Status: Recruiting

Water And Saline Head-to-head In The Blinded Evaluation Study Trial

All patients, aged 6 and above, who present for an emergent or interval appendectomy to any one of the participating surgeons will potentially be enrolled in the study. Prior to surgery, the patient or the patient's guardian if a minor, will be informed of the study and consent (assent of minors will be obtained) will be requested. If consent is obtained, the patient's name and medical record number will then be sent to the inpatient pharmacy. They will be randomly assigned using a master list to either water or saline arm.

Start Date: March 22, 2017

Completion Date: March 1, 2019

Status: Recruiting

Utilizing Off-the-shelf Technology to Improve Diabetes Management in a Rural Population

Hypothesis: Intervening in a rural primary care population with a clinically validated telehealth tool (Epharmix Diabetes) that algorithmically triages patients and facilitates patient-provider communication will result in a statistically significant improvement in the indicators of diabetes control. Study Design - Study Type: Experimental, non-controlled crossover study (intervention vs.

Start Date: March 13, 2017

Completion Date: July 31, 2017

Status: Recruiting

Gender Differences in the Metabolic Effects of Uric Acid

This project will use treatments from 4-8 months to lower uric acid in men and women. This study has three parts and each subject will participate in only one part. Tests that will be performed before and after treatment include measurements of body weight, blood pressure, blood vessel stiffness, heart stiffness, and blood lipids and glucose. Part 1: Dietary treatment The overall goal of part 1 is to remove fructose and simple sugars from the diets of women and men at risk for future heart disease.

Start Date: March 3, 2017

Completion Date: December 1, 2018

Status: Recruiting

Study Evaluating CERAMENT™|G in Open Diaphyseal Tibial Fractures

CERAMENT™|G is a resorbable, gentamicin containing ceramic bone graft indicated to fill bony voids or gaps which are not intrinsic to the stability of the bony structure and where there is risk of bacterial contamination.

Start Date: February 14, 2017

Completion Date: December 1, 2019

Status: Recruiting

Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

PRIMARY OBJECTIVES: I. To estimate complete response at 25 weeks after registration for those with a carcinoma in situ (CIS) component and to evaluate event-free survival at 18 months in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (Ta/T1/CIS) treated with atezolizumab. SECONDARY OBJECTIVES: I. To estimate event-free survival at 18 months for the subset of patients with papillary cancer (Ta/T1). II. To estimate progression-free survival, cystectomy-free survival, bladder cancer-specific survival, overall survival in all patients. TERTIARY OBJECTIVES: I.

Start Date: February 7, 2017

Completion Date: February 28, 2019

Status: Recruiting

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

The drug 3-V Bioscience-2640 has been tested previously in subjects with cancer because the lipogenesis pathway is important to the control of some cancer progression. Palmitate (C16:0), a saturated, 16-carbon fatty acid is a biomarker of lipogenesis present in blood triglyceride (TG), was found to be reduced significantly. A second biomarker of lipogenesis, malonyl carnitine, was significantly increased in patients as expected. The present study will test a lower dose (50 mg/d) than the maximum dose previously administered.

Start Date: February 1, 2017

Completion Date: January 31, 2018

Status: Recruiting